Ricky H Bhogal1,2,3, Sacheen Kumar4,5,6,7, Joseph P Doyle1,3, Pranav H Patel1,3, Sophie L F Doran1, Long R Jiao1,2, David Cunningham2, David Nicol1, Vasileios K Mavroeidis1,2, William H Allum1,2, Asif M Chaudry1,2. 1. Department of Surgery, The Royal Marsden Hospital, London, UK. 2. GI Unit, The Royal Marsden Hospital, London, UK. 3. Upper GI Surgical Oncology Research Group, The Institute for Cancer Research, London, UK. 4. Department of Surgery, The Royal Marsden Hospital, London, UK. sacheen.kumar@rmh.nhs.uk. 5. GI Unit, The Royal Marsden Hospital, London, UK. sacheen.kumar@rmh.nhs.uk. 6. Upper GI Surgical Oncology Research Group, The Institute for Cancer Research, London, UK. sacheen.kumar@rmh.nhs.uk. 7. Digestive Disease & Surgery Institute, Cleveland Clinic London Hospital, London, UK. sacheen.kumar@rmh.nhs.uk.
Abstract
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic caused unprecedented disruption to global healthcare delivery. In England, the majority of elective surgery was postponed or cancelled to increase intensive care capacity. Our unit instituted the 'RM Partners Cancer Hub' at the Royal Marsden Hospital in London, to deliver ongoing cancer surgery in a 'COVID-lite' setting. This article describes the operational set-up and outcomes for upper gastrointestinal (UGI) cancer resections performed during this period. METHODS: From April 2020 to April 2021, the Royal Marsden Hospital formed the RM Partners Cancer Hub. This approach was designed to coordinate resources and provide as much oncological treatment as feasible for patients across the RM Partners West London Cancer Alliance. A UGI surgical case prioritisation strategy, along with strict infection control pathways and pre-operative screening protocols, was adopted. RESULTS: A total of 231 patients underwent surgery for confirmed or suspected UGI cancer during the RM Partners Cancer Hub, with 213 completed resections and combined 90-day mortality rate of 3.5%. Good short-term survival outcomes were demonstrated with 2-year disease free survival (DFS) and overall survival (OS) for oesophageal (70.8% and 72.9%), gastric (66.7% and 83.3%) and pancreatic cancer resections (68.0% and 88.0%). One patient who developed perioperative COVID-19 during the RM Partners Cancer Hub operation made a full recovery with no lasting clinical sequelae. CONCLUSION: Our experience demonstrates that the RM Partners Cancer Hub approach is a safe strategy for continuing upper gastrointestinal (GI) resectional surgery during future periods of healthcare service disruption.
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic caused unprecedented disruption to global healthcare delivery. In England, the majority of elective surgery was postponed or cancelled to increase intensive care capacity. Our unit instituted the 'RM Partners Cancer Hub' at the Royal Marsden Hospital in London, to deliver ongoing cancer surgery in a 'COVID-lite' setting. This article describes the operational set-up and outcomes for upper gastrointestinal (UGI) cancer resections performed during this period. METHODS: From April 2020 to April 2021, the Royal Marsden Hospital formed the RM Partners Cancer Hub. This approach was designed to coordinate resources and provide as much oncological treatment as feasible for patients across the RM Partners West London Cancer Alliance. A UGI surgical case prioritisation strategy, along with strict infection control pathways and pre-operative screening protocols, was adopted. RESULTS: A total of 231 patients underwent surgery for confirmed or suspected UGI cancer during the RM Partners Cancer Hub, with 213 completed resections and combined 90-day mortality rate of 3.5%. Good short-term survival outcomes were demonstrated with 2-year disease free survival (DFS) and overall survival (OS) for oesophageal (70.8% and 72.9%), gastric (66.7% and 83.3%) and pancreatic cancer resections (68.0% and 88.0%). One patient who developed perioperative COVID-19 during the RM Partners Cancer Hub operation made a full recovery with no lasting clinical sequelae. CONCLUSION: Our experience demonstrates that the RM Partners Cancer Hub approach is a safe strategy for continuing upper gastrointestinal (GI) resectional surgery during future periods of healthcare service disruption.
Authors: Peter Moriarty; Justin Chang; Babar Kayani; Lois Roberts; Neil Bourke; Christopher Dann; Emma MacArthur; Fares S Haddad Journal: J Patient Saf Date: 2021-03-01 Impact factor: 2.844
Authors: Siobhan C McKay; Samir Pathak; Richard J W Wilkin; Sivesh K Kamarajah; Stephen J Wigmore; Jonathan Rees; Declan F J Dunne; Giuseppe Garcea; Jawad Ahmad; Nicola de Liguori Carino; Asma Sultana; Mike Silva; Pavlos Lykoudis; David Nasralla; James Milburn; Nehal Shah; Hemant M Kocher; Ricky Bhogal; Ryan D Baron; Alex Navarro; James Halle-Smith; Bilal Al-Sarireh; Gourab Sen; Nigel B Jamieson; Christopher Briggs; David Stell; Somaiah Aroori; Matthew Bowles; Aditya Kanwar; Simon Harper; Krishna Menon; Andreas Prachalias; Parthi Srinivasan; Adam E Frampton; Claire Jones; Ali Arshad; Iain Tait; Duncan Spalding; Alastair L Young; Damien Durkin; Manijeh Ghods-Ghorbani; Robert P Sutcliffe; Keith J Roberts Journal: HPB (Oxford) Date: 2021-03-19 Impact factor: 3.647
Authors: R H Bhogal; P H Patel; S L F Doran; S Zar; J M Pollok; L R Jiao; W H Allum; M A Chaudry; S Kumar Journal: Eur J Surg Oncol Date: 2020-05-30 Impact factor: 4.424
Authors: A Sud; M E Jones; J Broggio; C Loveday; B Torr; A Garrett; D L Nicol; S Jhanji; S A Boyce; F Gronthoud; P Ward; J M Handy; N Yousaf; J Larkin; Y-E Suh; S Scott; P D P Pharoah; C Swanton; C Abbosh; M Williams; G Lyratzopoulos; R Houlston; C Turnbull Journal: Ann Oncol Date: 2020-05-19 Impact factor: 32.976
Authors: Daniel J Boffa; Benjamin L Judson; Kevin G Billingsley; Domenico Galetta; Paul Fontanez; Craig Odermatt; Kristy Lindner; Marci R Mitchell; Cara M Henderson; Tracy Carafeno; Josephine Pinto; Jane A Wagner; Michael M Ancuta; Peggy Beley; Anne L Turner; Trevor Banack; Maxwell S Laurans; Dirk C Johnson; Peter S Yoo; John M Morton; Holly Zurich; Kimberly Davis; Nita Ahuja Journal: Ann Thorac Surg Date: 2020-05-15 Impact factor: 4.330
Authors: James C Glasbey; Dmitri Nepogodiev; Joana F F Simoes; Omar Omar; Elizabeth Li; Mary L Venn; Mohammad K Abou Chaar; Vita Capizzi; Daoud Chaudhry; Anant Desai; Jonathan G Edwards; Jonathan P Evans; Marco Fiore; Jose Flavio Videria; Samuel J Ford; Ian Ganly; Ewen A Griffiths; Rohan R Gujjuri; Angelos G Kolias; Haytham M A Kaafarani; Ana Minaya-Bravo; Siobhan C McKay; Helen M Mohan; Keith J Roberts; Carlos San Miguel-Méndez; Peter Pockney; Richard Shaw; Neil J Smart; Grant D Stewart; Sudha Sundar Mrcog; Raghavan Vidya; Aneel A Bhangu Journal: J Clin Oncol Date: 2020-10-06 Impact factor: 44.544